NCT00788333 - Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Breast Cancer

Interventions

DRUG

BMS-754807

Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop

DRUG

trastuzumab (Herceptin®)

IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop

Trial Locations (9)

1000

Local Institution, Brussels

1122

Local Institution, Budapest

3199

Local Institution, Frankston

3220

Local Institution, Geelong

3526

Local Institution, Miskolc

5037

Local Institution, Kurralta Park

K1H 8L6

Local Institution, Ottawa

M5G 1X5

Local Institution, Toronto

NE7 7DN

Local Institution, Newcastle upon Tyne